# TBE Seropersistence up to 10 Years After First Booster in Adults

> **NCT01582698** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 243 (actual)

## Conditions studied

- Tick-borne Encephalitis (TBE)

## Interventions

- **BIOLOGICAL:** FSME-IMMUN 0.5 ml

## Key facts

- **NCT ID:** NCT01582698
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582698, "TBE Seropersistence up to 10 Years After First Booster in Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01582698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*